Fenofibrate

 Fenofibrate (CAS NO.49562-28-9) was discovered by Groupe Fournier SA, before it was acquired in 2005 by Solvay Pharmaceutical, a business unit owned by the Belgian corporation, Solvay S.A. Fenofibrate is sold under the brand name Tricor and Trilipix by Abbott Labs, Lipofen by Kowa Pharmaceuticals America Inc, Lofibra by Teva, Lipanthyl and Lipidil by Solvay Pharmaceutical and Fenocor-67 by Ordain Health Care Pvt Ltd.

The pharmaceutical form and the strength may change from one country to another, and from one brand to another. In the United States, Tricor was reformulated in 2005 and is available in tablets of 48 and 145 mg. This reformulation is controversial and is the subject of antitrust litigation by generic drug manufacturer Teva. Also available in the United States, Lofibra is available in 54 and 160 mg tablets, as well as 67, 134, and 200 mg micronized capsules. Generic equivalents of Lofibra capsules are currently available in all three strengths in the United States. In Europe, it is available in either coated tablet or capsule; the strength range includes 67, 145, 160 and 200 mg. The differences among strengths are a result of altered bioavailability (the fraction absorbed by the body) due to particle size. For example, 200 mg can be replaced by 160 mg micronized fenofibrate. The 145 mg strength is a new strength appeared in 2005-2006 which also replaces 200 or 160 mg as the fenofibrate is nanonised (ie the particle size is below 400 nm).

Fenofibrate, with the IUPAC Name of propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate, is one kind of drug. This chemical belongs to the Product Categories which include Active Pharmaceutical Ingredients; Intermediates & Fine Chemicals; Pharmaceuticals; Intracellular receptor. It is mainly used to reduce Cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing tryglycerides level. It also appears to have a beneficial effect on the Insulin resistance featured by the metabolic syndrome. It is used alone or in conjunction with statins in the treatment of hyperCholesterolemia and hypertriglyceridemia.

Physical properties about Fenofibrate are: (1)ACD/LogP: 5.801; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 5.80; (4)ACD/LogD (pH 7.4): 5.80; (5)ACD/BCF (pH 5.5): 15087.66; (6)ACD/BCF (pH 7.4): 15087.66; (7)ACD/KOC (pH 5.5): 34091.39; (8)ACD/KOC (pH 7.4): 34091.39; (9)#H bond acceptors: 4; (10)#Freely Rotating Bonds: 7; (11)Index of Refraction: 1.547; (12)Molar Refractivity: 97.116 cm³; (13)Molar Volume: 306.449 cm³; (14)Polarizability: 38.5 10-24cm³; (15)Surface Tension: 40.9819984436035 dyne/cm; (16)Density: 1.177 g/cm³; (17)Flash Point: 165.356 °C; (18)Enthalpy of Vaporization: 73.22 kJ/mol; (19)Boiling Point: 469.774 °C at 760 mmHg; (20)Vapour Pressure: 0 mmHg at 25°C

When you are using Fenofibrate, please be cautious about it as the following:
1.Wear suitable protective clothing;
2. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice;

You could convert the following datas into the molecular structure:
(1)InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3;
(2)InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N;
(3)Smilesc1(C(c2ccc(Cl)cc2)=O)ccc(OC(C(OC(C)C)=O)(C)C)cc1

The toxicity data is as follows: